Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized,controlled trial

Abstract

Background:

Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects.

Aims:

The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary analysis, we determine if a subset of the psychoactive effects of ketamine, the so-called mystical-type experience, mediates the effect of ketamine, when combined with motivational enhancement therapy, on at-risk drinking behavior in alcohol-dependent individuals interested in treatment.

Methods:

Forty alcohol dependent adults were randomized to either a 52-minute infusion of ketamine or midazolam, which they received on a designated quit-day during the second week of a five-week motivational enhancement therapy regimen. Psychoactive effects were assessed following the infusion, and alcohol use was monitored for the subsequent 3 weeks at each twice-weekly visit.

Results:

We found that ketamine leads to significantly greater mystical-type effects (by Hood Mysticism Scale) and dissociation (by Clinician Administered Dissociative States Scale) compared to the active control. Ketamine also led to significant reduction in at-risk drinking. The Hood Mysticism Scale, but not Clinician Administered Dissociative States Scale score, was found to mediate the effect of ketamine on drinking behavior.

Conclusions:

This trial adds evidence to the literature on the importance of mystical-type experiences in addiction treatment. Future research should continue to investigate the relationship between the psychoactive effects of psychedelic therapeutics and clinical outcomes for other substance use and mental health disorders.

Keywords

Ketamine addiction treatment alcohol use disorder at-risk drinking psychedelic spirituality mystical experience motivational enhancement therapy hallucinogen

Get full access to this article

View all access options for this article.

References

Bogenschutz

Pommy

(2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses: Hallucinogens for addictions. Drug Test Anal 4: 543–555.

Bogenschutz

Forcehimes

Pommy

, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 29: 289–299.

Borgonovi

(2014) Aldous Huxley and the sense of travel: Between journey and metaphorical exploration. In Nugel

Neckier

(eds) Aldous Huxley Annual. Vol. 12–13. Münster: LIT Verlag, pp. 72.

Boschloo

Vogelzangs

Smit

, et al. (2011) Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders. J Affect Disord 131: 233–242.

Bremner

Krystal

Putnam

, et al. (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125–136.

Burns

Teesson

(2002) Alcohol use disorders comorbid with anxiety, depression and drug use disorders Findings from the Australian National Survey of Mental Health and Well Being. J Trauma Stress 68: 299–307.

Carhart-Harris

Goodwin

(2017) The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 42: 2105–2113.

Carter

(1998) The effects of spiritual practices on recovery from substance abuse. J Psychiatr Ment Health Nurs 5: 409–413.

Centers for Disease Control and Prevention (CDC) (2013) Alcohol Related Disease Impact (ARDI) Application. Atlanta: CDC.

10.

Dakwar

Anerella

Hart

, et al. (2014b) Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend 136: 153–157.

11.

Dakwar

Hart

Levin

, et al. (2017) Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial. Mol Psychiatry 22: 76–81.

12.

Dakwar

Levin

Foltin

, et al. (2014a) The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry 76: 40–46.

13.

Dakwar

Levin

Hart

, et al. (2020) A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry 177: 125–133.

14.

Dakwar

Nunes

Hart

, et al. (2018) A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology 142: 270–276.

15.

De Sousa

(2010) The pharmacotherapy of alcohol dependence: A state of the art review. Mens Sana Monogr 8: 69–82.

16.

Delaney

(2005) The spirituality scale: Development and psychometric testing of a holistic instrument to assess the human spiritual dimension. J Holist Nurs 23: 145–167.

17.

Duman

Liu

, et al. (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35–41.

18.

Escohotado

(1999) Chapter fifteen: The psychedelic rebellion. In: A Brief History of Drugs: From the Stone Age to the Stoned Age. Rochester: Park Street Press, pp. 114–125.

19.

Ezquerra-Romano

Lawn

Krupitsky

, et al. (2018) Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology 142: 72–82.

20.

Garcia-Romeu

Griffiths

Johnson

(2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7: 157–164.

21.

Grant

Stinson

Dawson

, et al. (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch Gen Psychiatry 61: 10.

22.

Griffiths

Johnson

Carducci

, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30: 1181–1197.

23.

Griffiths

Richards

Johnson

, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.

24.

Griffiths

Richards

McCann

, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268–283.

25.

Grob

McKenna

Callaway

, et al. (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184: 86–94.

26.

Hettema

Steele

Miller

(2005) Motivational interviewing. Annu Rev Clin Psychol 1: 91–111.

27.

Hood

(1975) The construction and preliminary validation of a measure of reported mystical experience. J Sci Study Relig 14: 29–41.

28.

Hosmer

Lemeshow

May

(2008) Applied Survival Analysis: Regression Modeling of Time-to-Event Data. New York: John Wiley & Sons, Inc.

29.

Iadarola

Niciu

Richards

, et al. (2015) Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: A perspective review. Ther Adv Chronic Dis 6: 97–114.

30.

James

(1907) The Varieties of Religious Experience: A Study in Human Nature. Oxford: Oxford World’s Classics.

31.

Johnson

Richards

Griffiths

(2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol 22: 603–620.

32.

Jonas

Amick

Feltner

, et al. (2014) Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 311: 1889–1900.

33.

Jones

Mateus

Malcolm

, et al. (2018) Efficacy of ketamine in the treatment of substance use disorders: A systematic review. Front Psychiatry 9: 1–10.

34.

Kaskutas

Bond

Weisner

(2003) The role of religion, spirituality and Alcoholics Anonymous in sustained sobriety. Alcohol Treat Quart 21: 1–16.

35.

Kelly

Stout

Magill

, et al. (2011) Spirituality in recovery: A lagged mediational analysis of Alcoholics Anonymous’ principal theoretical mechanism of behavior change. Alcohol Clin Exp Res 35: 454–463.

36.

Kranzler

Kirk

(2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol Clin Exp Res 25: 1335–1341.

37.

Krebs

Johansen

P-Ø

(2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol 26: 994–1002.

38.

Krupitsky

Burakov

Dunaevsky

, et al. (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 39: 13–19.

39.

Krupitsky

Burakov

Romanova

, et al. (2002) Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat 23: 273–283.

40.

Krupitsky

Grinenko

(1997) Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. J Psychoactive Drugs 29: 165–183.

41.

Lebedev

Lovden

Rosenthal

, et al. (2015) Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36: 3137–3153.

42.

Leigh

Bowen

Marlatt

(2005) Spirituality, mindfulness and substance abuse. Addict Behav 30: 1335–1341.

43.

Lee

Liu

, et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959–964.

44.

Luckenbaugh

Ibrahim

Brutsche

, et al. (2012) Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord 14: 880–887.

45.

McHugh

Hearon

Otto

(2010) Cognitive behavioral therapy for substance use disorders. Psychiatr Clin 33: 511–525.

46.

MacLean

Johnson

Griffiths

(2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.

47.

MacLean

Leoutsakos

J-MS

Johnson

, et al. (2012) Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51: 721–737.

48.

Maeng

Zarate

Jr Du

, et al. (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349–352.

49.

Maltbie

Gopinath

Howell

(2019) Effects of ketamine treatment on cocaine-induced reinstatement and disruption of functional connectivity in unanesthetized rhesus monkeys. Psychopharmacology 236: 2105–2118.

50.

Maxwell

Delaney

Kelley

(2017) Designing Experiments and Analyzing Data: A Model Comparison Perspective. (3rd ed.). New York: Routledge.

51.

Miller

Saunders

(2011) A naturalistic study of the associations between changes in alcohol problems, spiritual functioning, and psychiatric symptoms. Psychol Addict Behav 25: 455–461.

52.

Miller

(2004) The phenomenon of quantum change. J Clin Psychol 5: 453–460.

53.

Miller

C’de Baca

(2001) Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives. New York: Guilford.

54.

Moos

(2006) Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 101: 212–222.

55.

National Highway Traffic Safety Administration (2017) Traffic Safety Facts: Alcohol-Impaired Driving. U.S. Department of Transportation, pp. 1–8.

56.

National Institute on Alcohol Abuse and Alcoholism (2019) Drinking Levels Defined. Available at: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking (accessed 20 Jan 2020).

57.

Pahnke

(1966) Drugs and mysticism. Int J Parapsychol 8: 295–314.

58.

Robinson

EAR

Cranford

Webb

, et al. (2007) Six-month changes in spirituality, religiousness, and heavy drinking in a treatment-seeking sample. J Stud Alcohol Drugs 68: 282–290.

59.

Sacks

Gonzales

Bouchery

, et al. (2015) 2010 National and state costs of excessive alcohol consumption. Am J Prev Med 49: e73–e79.

60.

Sanacora

Schatzberg

(2015) Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40: 259–276.

61.

Savage

McCabe

(1973) Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Arch Gen Psychiatry 28: 808–814.

62.

Scheidegger

Walter

Lehmann

, et al. (2012) Ketamine decreases resting state functional network connectivity in healthy subjects: Implications for antidepressant drug action. PLoS One 7: e44799.

63.

Smedslund

Berg

Hammerstrøm

, et al. (2011) Motivational interviewing for substance abuse. Cochrane Database Syst Rev 5: CD008063.

64.

Stace

(1960) Mysticism and Philosophy. London: Macmillan and Company Limited.

65.

Substance Abuse and Mental Health Services Administration (2018) 2017-2018 National Survey on Drug Use and Health State Specific Tables. Available at: www.samhsa.gov/data (accessed 20 Jan 2020).

66.

Thomas

Lucas

Capler

, et al. (2013) Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr Drug Abuse Rev 6: 30–42.

67.

Zanos

Moaddel

Morris

, et al. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481–486.

68.

Zemore

(2007) A role for spiritual change in the benefits of 12-step involvement. Alcohol Clin Exp Res 31(Suppl 3): 76S–79S.